|1.||Galindo-Tovar, Alejandro: 4 articles (07/2014 - 01/2009)|
|2.||Kaumann, Alberto J: 4 articles (07/2014 - 01/2009)|
|3.||Cheng, Yu-Fang: 4 articles (12/2013 - 01/2011)|
|4.||Zhang, Han-Ting: 4 articles (01/2013 - 01/2011)|
|5.||Roewer, Norbert: 3 articles (01/2015 - 06/2012)|
|6.||Schlegel, Nicolas: 3 articles (01/2015 - 06/2012)|
|7.||Wollborn, Jakob: 3 articles (01/2015 - 06/2012)|
|8.||Wunder, Christian: 3 articles (01/2015 - 06/2012)|
|9.||Xu, Jiang-Ping: 3 articles (12/2013 - 03/2011)|
|10.||Atkins, Coleen M: 3 articles (03/2013 - 11/2007)|
12/01/2001 - "Taken together, these results might explain why certain cAMP-elevating agents such as rolipram are effective in blocking autoimmunity and inflammation."
02/01/2005 - "In this study we investigated the effects of rolipram, a selective phosphodiesterase type 4 inhibitor, on 14C-deoxyglucose (DG) uptake in inflammatory lesions and other normal tissues, and attempted to improve the inflammation/muscle ratio. "
08/01/2013 - "Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1."
01/04/2013 - "Although rolipram is well known to reduce pathology and inflammation in several other CNS injury models, the pathology resulting from CCI was worsened with rolipram at this particular dose and administration schedule. "
01/04/2013 - "We hypothesized that an anti-inflammatory drug, rolipram, may reduce pathology after TBI, since in several CNS injury models rolipram reduces inflammation and improves cell survival and functional recovery. "
|2.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
08/01/1996 - "Preventive but not therapeutic application of Rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats."
11/01/2005 - "Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS). "
06/01/1999 - "We examined the treatment effects of two structurally distinct phosphodiesterase type IV (PDE IV) inhibitors, BBB022 and rolipram, in murine and rat models of experimental autoimmune encephalomyelitis (EAE). "
10/01/2009 - "We conclude that the reasons underlying the discrepancy between the therapeutic efficacy of rolipram in experimental autoimmune encephalomyelitis versus multiple sclerosis are at present not clear."
08/01/1996 - "Experimental autoimmune encephalomyelitis (EAE) in Lewis rats, an animal model mimicking some aspects of multiple sclerosis, was treated with the type IV-specific phosphodiesterase inhibitor Rolipram. "
01/01/1993 - "Gerbils subjected to 10-min ischemia revealed a significant reduction in rolipram binding in most selectively vulnerable regions early in the recirculation (1-5 h). "
01/01/1993 - "Interestingly, the dentate gyrus, which was resistant to ischemia, also exhibited a significant reduction of the rolipram binding activity up to 1 month after ischemia. "
09/01/2008 - "We examined whether rolipram, a phosphodiesterase type IV inhibitor, treatment after hypoxic-ischemia is protective against white matter injury in neonatal rats. "
02/15/2002 - "These studies also support the conclusion that the mechanism of rolipram reversal of rat lung ischemia-reperfusion-induced permeability involves PDE4 inhibition in the microvascular endothelial cells of the lung."
03/01/2011 - "In addition, Nissl staining revealed ischemia-induced neuron loss in hippocampal CA1; this was blocked by rolipram. "
03/01/1998 - "The present study has investigated the therapeutic potential of a type 4 phosphodiesterase (PDE) inhibitor, rolipram, in experimental lung injury. "
05/01/2004 - "Here, we tested the protective effect of rolipram on CPB-induced lung injury in the rat. "
09/01/2012 - "The results of the study suggest that rolipram may be an effective rescue treatment for chlorine-induced lung injury and that both systemic and targeted administration to the respiratory tract were effective routes of delivery."
09/01/2012 - "The type 4 phosphodiesterase inhibitor rolipram was investigated as a rescue treatment for chlorine-induced lung injury. "
09/01/2012 - "Inhibition of chlorine-induced lung injury by the type 4 phosphodiesterase inhibitor rolipram."
|5.||Acute Lung Injury
03/01/1998 - "The results of the present study suggest that use of agents such as rolipram that inhibit PDE4 may have a therapeutic role in treatment of acute lung injury, since we have shown that it is effective in attenuation of neutrophil activation even after sequestration. "
04/01/2010 - "In the present study, we investigated the effect of classic PDE4 inhibitor rolipram and novel PDE4 inhibitor ZL-n-91 on LPS-induced acute lung injury (ALI) in mice and its mechanism. "
05/01/2004 - "These results suggest that rolipram prevents acute lung injury via the inhibition of neutrophil activation during and after CPB in this setting of a rat model."
01/01/1999 - "The present data show that the selective PDE4 inhibitor, rolipram, and the non-selective PDE inhibitor, theophylline, markedly reduced the pulmonary inflammation associated with acute lung injury in the rat. "
02/03/2015 - "One aim of this study was to evaluate whether a low-dose of DEX in combination with the antioxidant N-acetyl cysteine (NAC) and if different treatments (Triptolide, Reparixin and Rolipram) administered 1h after Cl2-exposure could improve protection against acute lung injury in Cl2-exposed mice. "
|1.||Type 4 Cyclic Nucleotide Phosphodiesterases
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|4.||Phosphodiesterase 4 Inhibitors
|5.||Cyclic AMP (AMP, Cyclic)
|6.||3',5'-Cyclic-AMP Phosphodiesterases (3',5' Cyclic Nucleotide Phosphodiesterase)
|8.||Caffeine (No Doz)
|9.||Picryl Chloride (Trinitrochlorobenzene)
|5.||Heterologous Transplantation (Xenotransplantation)